Deferred Tax Assets, Valuation Allowance of Esperion Therapeutics, Inc. from 31 Dec 2012 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Esperion Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2012 to 31 Dec 2025.
  • Esperion Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $417,064,000, a 0.96% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Esperion Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $417,064,000 +$3,979,000 +0.96% 31 Dec 2025 10-K 10 Mar 2026 2025 FY
Q4 2024 $413,085,000 +$17,504,000 +4.4% 31 Dec 2024 10-K 10 Mar 2026 2025 FY
Q4 2023 $395,581,000 +$43,468,000 +12% 31 Dec 2023 10-K 07 Mar 2025 2024 FY
Q4 2022 $352,113,000 +$67,959,000 +24% 31 Dec 2022 10-K 27 Feb 2024 2023 FY
Q4 2021 $284,154,000 +$81,311,000 +40% 31 Dec 2021 10-K 21 Feb 2023 2022 FY
Q4 2020 $202,843,000 +$28,625,000 +16% 31 Dec 2020 10-K 22 Feb 2022 2021 FY
Q4 2019 $174,218,000 +$22,036,000 +14% 31 Dec 2019 10-K 23 Feb 2021 2020 FY
Q4 2018 $152,182,000 +$52,334,000 +52% 31 Dec 2018 10-K 27 Feb 2020 2019 FY
Q4 2017 $99,848,000 +$24,583,000 +33% 31 Dec 2017 10-K 28 Feb 2019 2018 FY
Q4 2016 $75,265,000 +$24,689,000 +49% 31 Dec 2016 10-K 20 Feb 2018 2017 FY
Q4 2015 $50,576,000 +$16,368,000 +48% 31 Dec 2015 10-K 22 Feb 2017 2016 FY
Q4 2014 $34,208,000 +$11,404,000 +50% 31 Dec 2014 10-K 25 Feb 2016 2015 FY
Q4 2013 $22,804,000 +$8,453,000 +59% 31 Dec 2013 10-K 10 Mar 2015 2014 FY
Q4 2012 $14,351,000 31 Dec 2012 10-K 13 Mar 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.